Best-in-class vs first-in-class

From First-in-class to Finest: How Best-in-Class Drugs Reshape Pharmaceutical Leadership

Semaglutide, tirzepatide, pembrolizumab and Zanubrutinib illustrate how best-in-class drugs surpass pioneers, with China’s $51.9B licensing deals driving worldwide pharmaceutical growth.

Zanubrutinib Surpasses Ibrutinib: A Case Study in Best-in-Class Innovation

BeOne Medicines is reshaping hematology with zanubrutinib. Superior efficacy, cleaner safety, and strong market momentum put it ahead of ibrutinib — a textbook case of best-in-class drugs eclipsing first-in-class pioneers.